Insider Transactions in Q2 2025 at Gilead Sciences, Inc. (GILD)
Insider Transaction List (Q2 2025)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 30
2025
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.8%
|
$1,100,000
$110.54 P/Share
|
May 22
2025
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
28,000
-6.9%
|
$2,996,000
$107.52 P/Share
|
May 22
2025
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+8.38%
|
$1,650,000
$66.64 P/Share
|
May 15
2025
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-1.49%
|
$247,500
$99.82 P/Share
|
May 07
2025
|
Sandra Horning Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+22.75%
|
-
|
May 07
2025
|
Harish Manwani Director |
SELL
Payment of exercise price or tax liability
|
Direct |
296
-2.06%
|
$29,008
$98.9 P/Share
|
May 07
2025
|
Harish Manwani Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+9.53%
|
-
|
May 07
2025
|
Javier Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+11.04%
|
-
|
May 07
2025
|
Anthony Welters Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+11.43%
|
-
|
May 07
2025
|
Jacqueline K Barton Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+5.5%
|
-
|
May 07
2025
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,516
+25.9%
|
-
|
Apr 25
2025
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-0.43%
|
$16,274
$103.17 P/Share
|
Apr 25
2025
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
514
+1.37%
|
-
|
Apr 15
2025
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-1.46%
|
$265,000
$106.4 P/Share
|